Asunto(s)
Enfermedad de Graves , Insuficiencia Cardíaca , Hipertensión Pulmonar , Metimazol/administración & dosificación , Propiltiouracilo/administración & dosificación , Síndrome de Cimitarra , Adulto , Antitiroideos/administración & dosificación , Angiografía por Tomografía Computarizada/métodos , Tratamiento Conservador/métodos , Ecocardiografía Transesofágica/métodos , Electrocardiografía/métodos , Femenino , Enfermedad de Graves/complicaciones , Enfermedad de Graves/diagnóstico , Enfermedad de Graves/fisiopatología , Enfermedad de Graves/terapia , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/etiología , Insuficiencia Cardíaca/fisiopatología , Insuficiencia Cardíaca/terapia , Humanos , Hipertensión Pulmonar/diagnóstico , Hipertensión Pulmonar/etiología , Hipertensión Pulmonar/fisiopatología , Hipertensión Pulmonar/terapia , Procesamiento de Imagen Asistido por Computador/métodos , Síndrome de Cimitarra/complicaciones , Síndrome de Cimitarra/diagnóstico , Síndrome de Cimitarra/fisiopatología , Pruebas de Función de la Tiroides/métodos , Resultado del Tratamiento , Insuficiencia de la Válvula Tricúspide/diagnóstico por imagen , Insuficiencia de la Válvula Tricúspide/etiología , Vena Cava Inferior/diagnóstico por imagenAsunto(s)
Ascitis , Insuficiencia Cardíaca , Hipertiroidismo , Metimazol/administración & dosificación , Metoprolol/administración & dosificación , Dolor Abdominal/diagnóstico , Dolor Abdominal/etiología , Antitiroideos/administración & dosificación , Ascitis/diagnóstico por imagen , Ascitis/etiología , Ascitis/terapia , Fibrilación Atrial/diagnóstico , Diagnóstico Diferencial , Ecocardiografía Transesofágica/métodos , Electrocardiografía/métodos , Femenino , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/fisiopatología , Insuficiencia Cardíaca/terapia , Humanos , Hipertiroidismo/sangre , Hipertiroidismo/complicaciones , Hipertiroidismo/tratamiento farmacológico , Hipertiroidismo/fisiopatología , Imagen por Resonancia Cinemagnética/métodos , Cumplimiento de la Medicación , Persona de Mediana Edad , Paracentesis/métodos , Pruebas de Función de la Tiroides/métodosRESUMEN
Graves' disease (GD) is an autoimmune disorder that frequently results in hyperthyroidism and other symptoms. Here, we designed a 6-month study with patients divided into three treatment groups, namely, methimazole (MI, n = 8), MI + black bean (n = 9) and MI + probiotic Bifidobacterium longum (n = 9), to evaluate the curative effects of probiotics supplied with MI on thyroid function of patients with GD through clinical index determination and intestinal microbiota metagenomic sequencing. Unsurprisingly, MI intake significantly improved several thyroid indexes but not the most important thyrotropin receptor antibody (TRAb), which is an indicator of the GD recurrence rate. Furthermore, we observed a dramatic response of indigenous microbiota to MI intake, which was reflected in the ecological and evolutionary scale of the intestinal microbiota. In contrast, we did not observe any significant changes in the microbiome in the MI + black bean group. Similarly, the clinical thyroid indexes of patients with GD in the probiotic supplied with MI treatment group continued to improve. Dramatically, the concentration of TRAb recovered to the healthy level. Further mechanistic exploration implied that the consumed probiotic regulated the intestinal microbiota and metabolites. These metabolites impacted neurotransmitter and blood trace elements through the gut-brain axis and gut-thyroid axis, which finally improved the host's thyroid function.
Asunto(s)
Antitiroideos/farmacología , Bifidobacterium longum/química , Enfermedad de Graves/tratamiento farmacológico , Metimazol/farmacología , Probióticos/farmacología , Glándula Tiroides/efectos de los fármacos , Adulto , Antitiroideos/administración & dosificación , Eje Cerebro-Intestino/efectos de los fármacos , Femenino , Humanos , Masculino , Metimazol/administración & dosificación , Persona de Mediana Edad , Probióticos/administración & dosificaciónRESUMEN
Brain-body interactions are thought to be essential in emotions but their physiological basis remains poorly understood. In mice, regular 4 Hz breathing appears during freezing after cue-fear conditioning. Here we show that the olfactory bulb (OB) transmits this rhythm to the dorsomedial prefrontal cortex (dmPFC) where it organizes neural activity. Reduction of the respiratory-related 4 Hz oscillation, via bulbectomy or optogenetic perturbation of the OB, reduces freezing. Behavioural modelling shows that this is due to a specific reduction in freezing maintenance without impacting its initiation, thus dissociating these two phenomena. dmPFC LFP and firing patterns support the region's specific function in freezing maintenance. In particular, population analysis reveals that network activity tracks 4 Hz power dynamics during freezing and reaches a stable state at 4 Hz peak that lasts until freezing termination. These results provide a potential mechanism and a functional role for bodily feedback in emotions and therefore shed light on the historical James-Cannon debate.
Asunto(s)
Miedo/fisiología , Bulbo Olfatorio/fisiología , Corteza Prefrontal/fisiología , Respiración , Potenciales de Acción/fisiología , Animales , Antitiroideos/administración & dosificación , Antitiroideos/farmacología , Electrofisiología , Interneuronas/citología , Interneuronas/fisiología , Masculino , Cadenas de Markov , Metimazol/administración & dosificación , Metimazol/farmacología , Ratones , Ratones Endogámicos C57BL , Modelos Psicológicos , Optogenética , Periodicidad , Células Piramidales/citología , Células Piramidales/fisiología , Respiración/efectos de los fármacosRESUMEN
Graves' disease, a typical metabolism disorder, causes diffuse goiter accompanied by ocular abnormalities and ocular dysfunction. Although methimazole (MI) is a commonly used drug for the treatment of GD, the efficacy of methimazole is only limited to the control of clinical indicators, and the side effects of MI should be seriously considered. Here, we designed a 6-month clinical trial that divided the patients into two groups: a methimazole group (n=8) and a methimazole combined with potential prebiotic berberine group (n=10). The effects of both treatments on thyroid function and treatment outcomes in patients with GD were assessed by thyroid index measurements and gut microbiota metagenomic sequencing. The results showed that the addition of berberine restored the patients' TSH and FT3 indices to normal levels, whereas MI alone restored only FT3. In addition, TRAb was closer to the healthy threshold at the end of treatment with the drug combination. MI alone failed to modulate the gut microbiota of the patients. However, the combination of berberine with methimazole significantly altered the microbiota structure of the patients, increasing the abundance of the beneficial bacteria Lactococcus lactis while decreasing the abundance of the pathogenic bacteria Enterobacter hormaechei and Chryseobacterium indologenes. Furthermore, further mechanistic exploration showed that the addition of berberine resulted in a significant upregulation of the synthesis of enterobactin, which may have increased iron functioning and thus restored thyroid function. In conclusion, methimazole combined with berberine has better efficacy in patients with GD, suggesting the potential benefit of berberine combined with methimazole in modulating the composition of intestinal microbes in the treatment of GD, providing new strong evidence for the effectiveness of combining Chinese and Western drugs from the perspective of modulating the intestinal microbiota.
Asunto(s)
Berberina/uso terapéutico , Microbioma Gastrointestinal/efectos de los fármacos , Enfermedad de Graves/terapia , Metimazol/uso terapéutico , Prebióticos/administración & dosificación , Berberina/administración & dosificación , Biomarcadores , Manejo de la Enfermedad , Quimioterapia Combinada , Disbiosis , Enfermedad de Graves/diagnóstico , Enfermedad de Graves/etiología , Humanos , Redes y Vías Metabólicas , Metagenoma , Metagenómica/métodos , Metimazol/administración & dosificación , Modelos Biológicos , Pruebas de Función de la Tiroides , Resultado del TratamientoRESUMEN
BACKGROUND: Immune checkpoint blockade therapy may lead to thyroid dysfunction in 3-7% of treated patients. Alemtuzumab is a CD52 inhibitor leading to thyroid dysfunction in approximately 40% of patients. A female patient was affected by multiple sclerosis (MS) and subclinical hyperthyroidism due to an autonomously functioning thyroid nodule (AFTN). After alemtuzumab treatment, she developed aggressive clinical hyperthyroidism consistent with Marine-Lenhart syndrome. CASE PRESENTATION: A 36-year-old woman presented in July 2019 with symptoms of hyperthyroidism and eye complaints. Three years earlier, she was diagnosed with MS. Subclinical hyperthyroidism was diagnosed in April 2017. Thyroid scintigraphy showed an intranodular distribution of 99mTc-pertechnatate consisting of an AFTN in the right lobe of the thyroid. In June 2018, because of the MS, she was treated with alemtuzumab. In November 2018, she was started on methimazole treatment because of the symptoms of hyperthyroidism. In December 2018, thyroid function was normal under methimazole treatment. In June 2019, the patient received a second round of alemtuzumab administration. One month later, she developed symptoms of hyperthyroidism. These symptoms were accompanied by diplopia. Blood tests showed severe hyperthyroidism. Thyroid scintigraphy showed a diffuse distribution of 99mTc-pertechnatate and the presence of a "cool" area in the right lobe of the thyroid, confirmed by ultrasonography. The nodule was diagnosed as a low-risk indeterminate lesion. CONCLUSION: We present a case of Graves' disease with active, moderate-to-severe Graves' ophthalmopathy in a patient with pre-existing AFTN presenting with a coexisting, rare case of Marine-Lenhart syndrome associated with immune reconstitution after alemtuzumab treatment.
Asunto(s)
Alemtuzumab/efectos adversos , Alemtuzumab/uso terapéutico , Enfermedad de Graves/complicaciones , Oftalmopatía de Graves/inducido químicamente , Esclerosis Múltiple/tratamiento farmacológico , Adulto , Antineoplásicos Inmunológicos/efectos adversos , Antineoplásicos Inmunológicos/uso terapéutico , Antitiroideos/administración & dosificación , Antitiroideos/uso terapéutico , Femenino , Oftalmopatía de Graves/patología , Humanos , Metimazol/administración & dosificación , Metimazol/uso terapéutico , Metionina/administración & dosificación , Metionina/análogos & derivados , Metionina/uso terapéutico , Compuestos de Organoselenio/administración & dosificación , Compuestos de Organoselenio/uso terapéuticoRESUMEN
BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs) including thyroid dysfunction. There are only a few reports on Graves' disease induced by ICIs. We report a case of new-onset Graves' disease after the initiation of nivolumab therapy in a patient receiving gastric cancer treatment. CASE PRESENTATION: The patient was a 66-year-old Japanese man, who was administered nivolumab (240 mg every 3 weeks) as a third-line therapy for stage IVb gastric cancer. His thyroid function was normal before the initiation of nivolumab therapy. However, he developed thyrotoxicosis before the third administration of nivolumab. Elevated, bilateral, and diffuse uptake of radioactive tracer was observed in the 99mTc-pertechnetate scintigraphy. Furthermore, the thyroid-stimulating hormone receptor antibody (TRAb) and thyroid-stimulating antibody (TSAb) test results, which were negative before the first administration of nivolumab, were positive after starting the therapy. The patient was diagnosed with Graves' disease, and the treatment with methimazole and potassium iodide restored thyroid function. CONCLUSIONS: This is the first complete report of a case of new-onset Graves' disease after starting nivolumab therapy, confirmed by diffusely increased thyroid uptake in scintigraphy and the positive conversion of antibodies against thyroid-stimulating hormone receptor. It is important to perform thyroid scintigraphy and ultrasonography to accurately diagnose and treat ICI-induced thyrotoxicosis, because there are various cases in which Graves' disease is developed with negative and positive TRAb titres.
Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Enfermedad de Graves/inducido químicamente , Nivolumab/efectos adversos , Neoplasias Gástricas/tratamiento farmacológico , Anciano , Enfermedad de Graves/diagnóstico , Enfermedad de Graves/tratamiento farmacológico , Enfermedad de Graves/fisiopatología , Humanos , Japón , Masculino , Metimazol/administración & dosificación , Nivolumab/uso terapéutico , Yoduro de Potasio/administración & dosificación , Inducción de Remisión , Glándula Tiroides/efectos de los fármacos , Glándula Tiroides/fisiopatologíaAsunto(s)
Infecciones por Coronavirus , Enfermedad de Graves , Metimazol/administración & dosificación , Pandemias , Neumonía Viral , Propranolol/administración & dosificación , Receptores de Tirotropina/inmunología , Tiroglobulina/inmunología , Antagonistas Adrenérgicos beta/administración & dosificación , Anticuerpos/sangre , Antitiroideos/administración & dosificación , Betacoronavirus/aislamiento & purificación , COVID-19 , Prueba de COVID-19 , Técnicas de Laboratorio Clínico/métodos , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/fisiopatología , Femenino , Enfermedad de Graves/sangre , Enfermedad de Graves/etiología , Enfermedad de Graves/fisiopatología , Enfermedad de Graves/terapia , Humanos , Pulmón/diagnóstico por imagen , Persona de Mediana Edad , Neumonía Viral/complicaciones , Neumonía Viral/diagnóstico , Neumonía Viral/etiología , Neumonía Viral/inmunología , Neumonía Viral/fisiopatología , SARS-CoV-2 , Pruebas de Función de la Tiroides/métodos , Resultado del Tratamiento , Ultrasonografía/métodosRESUMEN
BACKGROUND: Mechanical ventilation (MV) is life saving; yet it may induce severe lung injury and lead to multisystem organ failure and death. Thyroid hormones (THs) promote alveolar fluid clearance and alleviates hypoxia-induced lung injury. Given that the mechanism involved in hypoxia-induced lung injury is different from that of ventilator-induced lung injury, we examined the effects of thyroid function on lung extravascular fluid (LF), aquaporin 5 (AQP 5) expression, and alveolar viscoelasticity (AVE) in mechanically ventilated rat. METHODS: Hypothyroid (hypo) and hyperthyroid (hyper) animals were generated by administration of metimazole and L-thyroxine, respectively. Lung injury was induced by high-tidal volume MV. The LF was estimated by lung wet weight-to-dry weight ratio assessment. Expression of AQP 5 was evaluated by western blotting and in situ immunohistochemistry. The AVE was judged by elastic lung pressure/volume curve recording. RESULTS: Injurious MV significantly reduced lung AQP 5 expression and altered LF and AVE in a thyroid function-dependent manner. Regardless of animals' ventilation mode, hyper state caused significant reductions in LF and lung AQP 5 protein. It also improved AVE irrespective of animals' ventilation mode. The effects of hypo condition on LF, AQP 5 expression, and AVE were in contrast to that of hyper state. CONCLUSIONS: These data indicate that thyroid function has profound effects on LF, AQP 5, and AVE in mechanically ventilated lungs. Given that the effects of thyroidal status were as prominent as that of injurious MV, we suggest that thyroid function should be considered when patients are to be subjected to MV.
Asunto(s)
Alveolos Pulmonares/fisiopatología , Respiración Artificial/efectos adversos , Glándula Tiroides/metabolismo , Hormonas Tiroideas/metabolismo , Lesión Pulmonar Inducida por Ventilación Mecánica/metabolismo , Animales , Antitiroideos/administración & dosificación , Acuaporina 5/análisis , Acuaporina 5/metabolismo , Modelos Animales de Enfermedad , Elasticidad , Humanos , Masculino , Metimazol/administración & dosificación , Ratas , Glándula Tiroides/efectos de los fármacos , Tiroxina/administración & dosificación , Volumen de Ventilación Pulmonar , Lesión Pulmonar Inducida por Ventilación Mecánica/etiología , Lesión Pulmonar Inducida por Ventilación Mecánica/fisiopatología , ViscosidadRESUMEN
The treatment of Graves' hyperthyroidism (GD) complicated with malignancy is challenging, as anti-thyroid thionamide drugs (ATDs) and anti-cancer chemotherapy are both associated with a risk of neutropenia. Treatment with conventional ATDs, radioactive iodine (RAI) or potassium iodide (KI) was attempted in 8 patients with malignancy (34-80 years of age; 2 males and 6 females) in whom GD had been fortuitously diagnosed during a detailed systematic examination. Three patients requiring surgery were initially treated conventionally with methylmercaptoimidazole (MMI), MMI and KI or RAI (group A; one patient each). The patients became euthyroid on days 17-31 and underwent surgery on days 25-47. RAI therapy was administered to one patient after surgery. The patients were then treated with KI during chemotherapy. Five other patients who did not require surgery were initially treated with 100 mg KI monotherapy (group B). The serum free T4 level declined immediately in all of these patients, and they became euthyroid on days 7-18, remaining almost entirely euthyroid for more than 120 days. Anti-cancer chemotherapy was successfully completed for three of the patients while taking KI, despite the patients experiencing repeated episodes of anti-cancer chemotherapy-induced neutropenia. Our present findings suggest that, in patients with GD and malignancy, MMI + KI or RAI may be required if immediate surgery is scheduled, but KI monotherapy may be worth trying, if anti-cancer chemotherapy is scheduled, thus avoiding the possibility of thionamide-induced neutropenia.
Asunto(s)
Enfermedad de Graves/terapia , Metimazol/efectos adversos , Neoplasias/terapia , Neutropenia/inducido químicamente , Adulto , Anciano , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Antitiroideos/administración & dosificación , Antitiroideos/efectos adversos , Femenino , Enfermedad de Graves/complicaciones , Enfermedad de Graves/epidemiología , Humanos , Hipertiroidismo/complicaciones , Hipertiroidismo/epidemiología , Hipertiroidismo/terapia , Radioisótopos de Yodo/uso terapéutico , Masculino , Metimazol/administración & dosificación , Persona de Mediana Edad , Neoplasias/complicaciones , Neoplasias/epidemiología , Neutropenia/terapia , Yoduro de Potasio , Factores de Riesgo , Tiroidectomía/estadística & datos numéricosRESUMEN
Introduction: The thionamide antithyroid drugs, methimazole (MMI), its pro-drug derivative carbimazole (CMZ), and propylthiouracil (PTU) are the mainstay of treatment for hyperthyroidism in pregnancy. However, antithyroid drugs carry risks of adverse effects that can affect fetal and maternal well-being.Areas covered: This review provides an update on the safety of antithyroid drugs in pregnancy, focusing on the most serious concerns of severe liver disease and congenital anomalies.Expert opinion: PTU-induced liver disease is uncommon but can run a catastrophic course in pregnancy with a risk of liver failure and threats to maternal or fetal survival. Acute pancreatitis is a relatively rare occurrence that has been linked to thionamide use in a handful of reports in non-pregnant individuals. Observational studies on the risk of birth defects with antithyroid drug exposure in pregnancy overall show an increase in birth defect risk with exposure to CMZ/MMI, and to a lesser extent, PTU. Further studies are required to determine whether the currently recommended approach of switching between thionamide drugs in pregnancy improves outcomes. Ultimately, a preventative strategy of offering definitive therapy to hyperthyroid women of childbearing potential offers the best approach to truly reduce the risks of antithyroid drug adverse effects in pregnancy.
Asunto(s)
Antitiroideos/efectos adversos , Hipertiroidismo/tratamiento farmacológico , Complicaciones del Embarazo/tratamiento farmacológico , Anomalías Inducidas por Medicamentos/epidemiología , Anomalías Inducidas por Medicamentos/etiología , Antitiroideos/administración & dosificación , Carbimazol/administración & dosificación , Carbimazol/efectos adversos , Femenino , Humanos , Metimazol/administración & dosificación , Metimazol/efectos adversos , Embarazo , Propiltiouracilo/administración & dosificación , Propiltiouracilo/efectos adversosRESUMEN
The infectious disease melioidosis is caused by the bacterium Burkholderia pseudomallei. Melioidosis is characterised by high mortality and morbidity and can involve the central nervous system (CNS). We have previously discovered that B. pseudomallei can infect the CNS via the olfactory and trigeminal nerves in mice. We have shown that the nerve path is dependent on mouse strain, with outbred mice showing resistance to olfactory nerve infection. Damage to the nasal epithelium by environmental factors is common, and we hypothesised that injury to the olfactory epithelium may increase the vulnerability of the olfactory nerve to microbial insult. We therefore investigated this, using outbred mice that were intranasally inoculated with B. pseudomallei, with or without methimazole-induced injury to the olfactory neuroepithelium. Methimazole-mediated injury resulted in increased B. pseudomallei invasion of the olfactory epithelium, and only in pre-injured animals were bacteria found in the olfactory nerve and bulb. In vitro assays demonstrated that B. pseudomallei readily infected glial cells isolated from the olfactory and trigeminal nerves (olfactory ensheathing cells and trigeminal Schwann cells, respectively). Bacteria were degraded by some cells but persisted in other cells, which led to the formation of multinucleated giant cells (MNGCs), with olfactory ensheathing cells less likely to form MNGCs than Schwann cells. Double Cap mutant bacteria, lacking the protein BimA, did not form MNGCs. These data suggest that injuries to the olfactory epithelium expose the primary olfactory nervous system to bacterial invasion, which can then result in CNS infection with potential pathogenic consequences for the glial cells.
Asunto(s)
Burkholderia pseudomallei , Melioidosis/microbiología , Bulbo Olfatorio/microbiología , Nervio Olfatorio/microbiología , Subunidad beta de la Proteína de Unión al Calcio S100/metabolismo , Animales , Antitiroideos/administración & dosificación , Antitiroideos/farmacología , Genes Reporteros , Células Gigantes , Humanos , Melioidosis/patología , Metimazol/administración & dosificación , Metimazol/farmacología , Ratones , Ratones Transgénicos , Mucosa Respiratoria/lesiones , Mucosa Respiratoria/microbiología , Subunidad beta de la Proteína de Unión al Calcio S100/genéticaRESUMEN
BACKGROUND: The management of melasma is still challenging, and new treatment modalities with favorable side effect profile are required. Methimazole, a peroxidase inhibitor, seems to have a beneficial effect in the management of melasma but there is a paucity of studies for evaluation of its efficacy. This double-blinded trial was aimed to evaluate the efficacy and safety of methimazole vs hydroquinone 4% which is the gold standard treatment in the management of melasma. METHODS: Fifty patients with melasma were enrolled and randomly divided into two groups to receive 4% hydroquinone or 5% methimazole once daily for 8 weeks. Forty patients completed the study. The clinical response was assessed at 4th, 8th, and 12th weeks after treatment by MASI score, patient satisfaction, and physician scores. RESULTS: Both groups showed a reduction in the MASI score at the 8th week which was more significant in hydroquinone group but higher relapse rate was also observed in this group after discontinuing the drug. The side effects were similar between groups. Also, patient and physician satisfaction scores were also more in favor of hydroquinone 4%. CONCLUSION: Methimazole could be an alternative treatment of melasma alone or in combination with other depigmenting drugs. Although not as effective as hydroquinone, the noncytotoxic and nonmutagenic aspects of methimazole may make it a promising alternative for the treatment of melasma.
Asunto(s)
Hidroquinonas/administración & dosificación , Melanosis/tratamiento farmacológico , Metimazol/administración & dosificación , Adulto , Método Doble Ciego , Femenino , Humanos , Hidroquinonas/efectos adversos , Melanosis/diagnóstico , Metimazol/efectos adversos , Persona de Mediana Edad , Satisfacción del Paciente , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
BACKGROUND AND OBJECTIVES: Recent studies show that long-term (LT) antithyroid drugs reduce relapse of hyperthyroidism in patients with Graves' disease. Our objective was to evaluate the effectiveness and safety of LT methimazole treatment and to compare remission rates in Graves' disease patients after LT and short-term (ST) therapy. METHODS: In this randomized, parallel group trial, 66 consecutive patients with untreated juvenile Graves' hyperthyroidism were enrolled. After a median 22 months of methimazole treatment, 56 patients were randomly assigned to either continue low-dose methimazole treatment (n = 24, LT group) or to discontinue treatment (n = 24, ST group). Twenty-four patients in LT group completed 96 to 120 months of methimazole treatment. Patients in both groups were managed for 48 months after discontinuation of treatment. RESULTS: Except for 3 cases of cutaneous reactions, no other adverse events were observed throughout 120 months of methimazole therapy. Serum free thyroxine, triiodothyronine, thyrotropin, and thyrotropin receptor antibody remained normal, and the required daily dosage of methimazole was gradually decreased from 5.17 ± 1.05 mg at 22 months to 3.5 ± 1.3 mg between 96 and 120 months of treatment (P < .001). Hyperthyroidism was cured in 92% and 88% of LT patients and in 46% and 33% of ST patients, 1 and 4 years after methimazole withdrawal, respectively. CONCLUSIONS: LT methimazole treatment of 96 to 120 months is safe and effective for treatment of juvenile Graves' disease. The four-year cure rate of hyperthyroidism with LT methimazole treatment is almost 3 times more than that of ST methimazole treatment.
Asunto(s)
Antitiroideos/administración & dosificación , Enfermedad de Graves/diagnóstico , Enfermedad de Graves/tratamiento farmacológico , Metimazol/administración & dosificación , Adolescente , Esquema de Medicación , Femenino , Enfermedad de Graves/sangre , Humanos , Masculino , Pruebas de Función de la Tiroides/tendenciasAsunto(s)
Atresia de las Coanas/inducido químicamente , Pérdida Auditiva/inducido químicamente , Metimazol/efectos adversos , Complicaciones del Embarazo/tratamiento farmacológico , Antitiroideos/administración & dosificación , Antitiroideos/efectos adversos , Preescolar , Femenino , Enfermedad de Graves/tratamiento farmacológico , Humanos , Masculino , Metimazol/administración & dosificación , EmbarazoRESUMEN
Post-upper respiratory tract infection related olfactory dysfunction typically occurs due to neural damage after an upper respiratory tract infection associated with a common cold or influenza. At present, Tokishakuyakusan, a Japanese traditional Kampo medicine, has been found to be effective for post-viral olfactory dysfunction. However, the pharmacodynamics of Tokishakuyakusan in the treatment of post-viral olfactory dysfunction remains unresolved. We investigated the effects of Tokishakuyakusan on the regeneration of olfactory neurons and expression of nerve growth factor (NGF) in neural systems, using in vivo murine studies and in vitro cell culture studies. Eight-week-old BALB/C female mice were fed a pellet diet with or without Tokishakuyakusan. Degeneration of cells in olfactory epithelium was induced by intraperitoneal methimazole injection. Regeneration of olfactory neurons was observed by histological and immunohistochemical procedures. NGF expression in the olfactory bulb was measured by enzyme-linked immunosorbent assay. NGF gene and protein expression were measured using rat primary cultured astrocytes by real-time polymerase chain reaction and enzyme-linked immunosorbent assay. We found that olfactory marker protein, Ki-67, and NGF were more highly expressed in the olfactory epithelium during the regeneration period in mice receiving Tokishakuyakusan. In cultured astrocytes, Tokishakuyakusan as well as its individual components, Atractylodes lancea rhizome and Japanese angelica root, increased NGF expression. Screening assays revealed that NGF production was increased by atractylodin and levistolide A, which are ingredients in Atractylodes lancea rhizome and Japanese angelica root, respectively. These results suggest that Tokishakuyakusan promotes regeneration of olfactory neurons by increasing NGF expression in the olfactory bulb.
Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Neuronas/efectos de los fármacos , Bulbo Olfatorio/efectos de los fármacos , Administración Oral , Animales , Astrocitos/efectos de los fármacos , Astrocitos/metabolismo , Células Cultivadas , Medicamentos Herbarios Chinos/administración & dosificación , Epitelio/efectos de los fármacos , Epitelio/metabolismo , Femenino , Inyecciones Intraperitoneales , Metimazol/administración & dosificación , Metimazol/farmacología , Ratones , Ratones Endogámicos BALB C , Factores de Crecimiento Nervioso/genética , Factores de Crecimiento Nervioso/metabolismo , Neuronas/metabolismo , Bulbo Olfatorio/metabolismoRESUMEN
Background/aim: The aim of this study was to assess the effect of a combination use of methimazole (MMI) and selenium (Se) in the treatment of Graves' disease (GD). Materials and methods: A total of 103 newly diagnosed hyperthyroidism patients were randomized to MMI and MMI + Se combination groups. After treatment for 6 months, the levels of triiodothyronine (FT3), free thyroxine (FT4), thyrotropin receptor antibody (TRAb), thyroid peroxidase antibody (TPOAb), and thyroglobulin antibody (TGAb) were observed. An in vitro culture model of thyroid cells was established and the protein expression and mRNA levels of TRAb, TPOAb, and TGAb were determined by western blot and RT-PCR. Results: A significant decrease in the levels of FT3, FT4, TRAb, TPOAb, and TGAb were observed in both groups along with a marked increase in TSH levels. Furthermore, the in vitro experiments showed that the protein expression and mRNA levels of TRAb, TPOAb, and TGAb decreased significantly. Also, compared to the MMI group, there was a greater improvement of these indices in the MMI + Se group. Conclusion: We suggest that the combined use of MMI and Se could improve the thyroid activity in patients, which may provide an effective therapy for the treatment of GD in clinical settings.
Asunto(s)
Antitiroideos/uso terapéutico , Enfermedad de Graves/tratamiento farmacológico , Metimazol/uso terapéutico , Selenio/uso terapéutico , Adulto , Antitiroideos/administración & dosificación , Autoanticuerpos/sangre , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Suplementos Dietéticos , Femenino , Enfermedad de Graves/patología , Enfermedad de Graves/cirugía , Humanos , Masculino , Metimazol/administración & dosificación , Metimazol/toxicidad , Persona de Mediana Edad , Proyectos Piloto , Receptores de Tirotropina/inmunología , Selenio/administración & dosificación , Selenio/toxicidad , Glándula Tiroides/citología , Glándula Tiroides/patología , Glándula Tiroides/cirugía , Hormonas Tiroideas/sangreRESUMEN
Graves' disease is an organ-specific autoimmune disease with hyperthyroidism, diffuse goiter and autoantibodies against TSH receptor, thyroid peroxidase (TPO) and/or thyroglobulin (Tg). Graves' hyperthyroidism is characterized by T3 dominance due to the conversion of T4 into T3 through type 1 and 2 deiodinase enzymes (DIO1, DIO2). Methimazole (MMI) and propylthiouracil (PTU) therapies inhibit thyroid hormone synthesis blocking the activity of deiodinase and TPO enzymes. The study investigated the occurrence of autoantibodies against DIO2 peptides (cys- and hom-peptides) with the effect of antithyroid drugs on their frequencies in 78 patients with Graves' disease and 30 controls. In hyperthyroidism, the presence of DIO2 peptide antibodies was as follows: 20 and 11 cases out of 51 for cys- and hom-peptide antibodies, respectively, of whom 8 cases possessed antibodies against both peptides. Antithyroid drugs differently influenced their frequencies, which were greater in PTU than in MMI (3/6 vs 13/45 cases, P < 0.016 for cys- and 0/6 vs 2/45 cases for hom-peptide antibodies). Antibodies against both peptides demonstrated more reduced levels of anti-TPO (P < 0.003) and anti-Tg antibodies (P < 0.002) compared with those without peptide antibodies. PTU compared with MMI increased the levels of TSH receptor antibodies (32.5 UI/l vs 2.68 IU/l, P < 0.009). MMI treatment led to more reduced FT3 levels and FT3/FT4 ratios in hyperthyroid Graves' ophthalmopathy (P < 0.028 for FT3, P < 0.007 for FT3/FT4 ratio). In conclusion, the presence of DIO2 peptide antibodies is connected to Graves' hyperthyroidism influencing the levels of antibodies against TPO, Tg and TSH receptor, as well as the therapeutic efficacy of antithyroid drugs.
Asunto(s)
Antitiroideos/administración & dosificación , Autoanticuerpos/sangre , Enfermedad de Graves/tratamiento farmacológico , Enfermedad de Graves/patología , Yoduro Peroxidasa/inmunología , Adulto , Femenino , Humanos , Masculino , Metimazol/administración & dosificación , Persona de Mediana Edad , Propiltiouracilo/administración & dosificación , Resultado del Tratamiento , Yodotironina Deyodinasa Tipo IIRESUMEN
Drug-induced liver injury is a major concern in clinical studies as well as in post-marketing surveillance. Previous evidence suggested that drug exposure during periods of inflammation could increase an individual's susceptibility to drug hepatoxicity. The antithyroid drugs, methimazole (MMI) and propylthiouracil (PTU) can cause adverse reactions in patients, with liver as a usual target. We tested the hypothesis that MMI and PTU could be rendered hepatotoxic in animals undergoing a modest inflammation. Mice were treated with a nonhepatotoxic dose of LPS (100 µg/kg, i.p) or its vehicle. Nonhepatotoxic doses of MMI (10, 25 and 50 mg/kg, oral) and PTU (10, 25 and 50 mg/kg, oral) were administered two hours after LPS treatment. It was found that liver injury was evident only in animals received both drug and LPS, as estimated by increases in serum alanine aminotransferase (ALT), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and TNF-α. An increase in liver myeloperoxidase (MPO) enzyme activity and tissue lipid peroxidation (LPO) in addition of liver glutathione (GSH) depletion were also detected in LPS and antithyroid drugs cotreated animals. Furthermore, histopathological changes including, endotheliitis, fatty changes, severe inflammatory cells infiltration (hepatitis) and sinusoidal congestion were detected in liver tissue. Methyl palmitate (2 g/kg, i.v, 44 hours before LPS), as a macrophage suppressor, significantly alleviated antithyroids hepatotoxicity in LPS-treated animals. The results indicate a synergistic liver injury from antithyroid drugs and bacterial lipopolysaccharide coexposure.